Session Overview
This webinar, led by scientific grants expert Dr. Kelsey McLaughlin, provides an overview of the latest SBIR/STTR reauthorization updates and what they mean for small businesses pursuing non-dilutive funding. Attendees gain insights into key policy changes, including proposal submission caps, foreign risk disclosure and compliance requirements, Strategic Breakthrough Awards, expanded TABA opportunities, and evolving agency-specific timelines and budget caps. The session also highlights emerging research priorities and offers practical strategies for preparing competitive applications, aligning proposals with agency priorities, and navigating an increasingly competitive and compliance-driven funding environment.
Key Takeaways
Congress has reauthorized SBIR/STTR through 2031, restoring funding continuity across agencies including NIH, NSF, NASA, DoW, DoE, and ARPA-H. However, the reauthorization is not a simple extension of the prior SBIR/STTR programs—it includes structural reforms intended to improve accountability, security, and commercialization impact.
The reauthorization bill did not alter the total allocations for SBIR/STTR funding from Fiscal Year 2025:
-
- Federal agencies with R&D budgets over $100 million must set aside 3.2% of this budget for
SBIR awards. - Federal agencies with R&D budgets over $1 billion must set aside 0.45% of this budget for
STTR awards.
- Federal agencies with R&D budgets over $100 million must set aside 3.2% of this budget for
➡️This translates to > $4 billion in funding available for SBIR/STTR awards across the 11 participating agencies.
-
- A major focus of the reauthorization is strengthening foreign risk management across agencies.
- Expanded foreign disclosure requirements
- More formalized risk assessment processes
- Increased scrutiny of international affiliations, funding sources, and IP exposure
- Clearer communication when applications fail foreign risk review (though mitigation remains limited in most cases)
➡️ These changes reflect growing federal concern around protecting sensitive technologies and research integrity.
- A major focus of the reauthorization is strengthening foreign risk management across agencies.
-
- To address high numbers of submissions from single entities and concentration of awards among a small number of applicants, agencies are introducing limits on proposal submissions.
- NIH: capped at 9 submissions per company per year
- ARPA-H: capped at 6 submissions per company per year (starting October 1, 2026)
- NASA: limits 2 submissions per appendix
- Other agencies are expected to implement caps in the next few months
➡️ This marks a shift toward more strategic, selective application planning rather than high-volume submission strategies.
- To address high numbers of submissions from single entities and concentration of awards among a small number of applicants, agencies are introducing limits on proposal submissions.
-
- A new funding mechanism—the Strategic Breakthrough Award—has been introduced to support later-stage technology transition.
- Up to $30M in federal funding (expect most awards will be <$10M)
- Requires 100% non-SBIR federal or private matching funds
- Designed to accelerate commercialization of Phase II technologies
- Most applicable within DoW and select agencies with SBIR/STTR budgets >$100M
➡️ This signals a stronger push toward commercialization impact over stand-alone early-stage R&D.
- A new funding mechanism—the Strategic Breakthrough Award—has been introduced to support later-stage technology transition.
-
- TABA funding has been significantly expanded and modernized.
- Broader eligibility across agencies
- Increased resources to support successful commercialization
- Cybersecurity readiness is an allowable cost (including CMMC preparation for DoW)
- Expands support for market research, IP strategy, and customer discovery (including I-Corps participation)
- Now allows internal staffing or dedicated personnel support
➡️ TABA is becoming a more strategic tool for commercialization readiness, not just supplemental support.
- TABA funding has been significantly expanded and modernized.
-
- Each agency is rolling out updates at different speeds, creating a more fragmented submission landscape.
- DoW: monthly topic releases + strict CMMC requirements tied to topics
- NIH/HHS: new deadlines, no late submissions, updated biosketch requirements (SciENcv + ORCID integration)
- ARPA-H: shifting to a two-step process (solution summary + oral presentation)
- DOE: expected updates to solicitation timing and review structures
- Some agencies may delay awards or shift funding cycles into FY2027 due to carryover provisions
➡️ Applicants must now track agency-specific updates more closely than ever.
- Each agency is rolling out updates at different speeds, creating a more fragmented submission landscape.
Across all agencies, success in SBIR/STTR is shifting from “apply more” to “apply smarter.”
Key success factors include:
-
- Strong alignment with agency priorities
- Early compliance and disclosure readiness
- Strategic selection of submission opportunities
- Clear commercialization pathways and funding strategy
The SBIR/STTR program remains one of the largest and most impactful sources of non-dilutive funding for innovation, but the landscape is becoming more complex, more competitive, and more compliance-driven.
Organizations that adapt early—particularly around submission strategy, foreign risk readiness, and commercialization planning—will be best positioned to succeed in this new environment.
